second to Medtronic in the implantable cardioverter defibrillator market. Further, we wouldn't underestimate Boston Scientific as it strives to regain lost share, especially if it turns to dealing on price.St. Jude’s Durata lead remains
7M. Amortization of acquired intangible assets 10.1M. During Q4, Medicines Company completed the acquisition of Rempex Pharmaceuticals and a co-promotion partnership with Boston Scientific . ( PR ) Previous Post your comment!
quarters, competition from St. Jude Medical STJ and Boston Scientific BSX has damped Medtronic's performance in this market ..... stable oligopoly it competes in, primarily with Boston Scientific and St. Jude Medical. The competitors may trade
maintaining our fair value estimate for Angiotech. The firm generates about 40% of its sales from royalties on Boston Scientific 's BSX Taxus stents, which have come under scrutiny since mid-2006 along with Johnson & Johnson's JNJ Cypher stents
By Stephen Simpson, CFA : Watching Cyberonics ( CYBX ) evolve over the years has been pretty compelling. I was part of a sell-side research team that covered the stock in the late 90s and early 00s and followed the company as it struggled to gain the acceptance of the FDA, physicians, and patients,
evidenced by the series of goodwill write-downs taken since 2006 (totaling nearly $14 billion at last count). Boston Scientific produces less-invasive medical devices that are inserted into the human body through small openings or cuts. It
We were reassured by Boston Scientific 's fourth-quarter results, as underlying demand seems to have further strengthened. Although we have not made material changes
Boston Scientific Corporation ( BSX ) Q4 2013 Results Earnings Call February 04, 2014, 08:00 AM ET Executives Susan Lisa - Investor Relations Michael F. Mahoney
Feb 4 (Reuters) - Boston Scientific Corp on Tuesday reported higher-than-expected quarterly results, citing improving demand for its devices that manage irregular heart rhythms.
Boston Scientific ( BSX -0.85% ) net profit rose to $108M from $60M a year earlier. Sales breakdown: MedSurg +12% at constant currencies, with